US Patent

US9925138 — Stable solid fingolimod dosage forms

Formulation · Assigned to Handa Pharmaceuticals LLC · Expires 2036-01-19 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable solid pharmaceutical dosage forms of fingolimod or its salts, conjugates, or complexes, which can rapidly disintegrate in the oral cavity.

USPTO Abstract

The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.

Drugs covered by this patent

Patent Metadata

Patent number
US9925138
Jurisdiction
US
Classification
Formulation
Expires
2036-01-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Handa Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.